Ultragenyx Pharmaceutical (RARE) EBT Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 32.79% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 47.54% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -49.71% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 12.01% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 20.92% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -1.05% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67% |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | -4.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.02% |
| Dec 31, 2025 | 5.91% |
| Sep 30, 2025 | 9.07% |
| Jun 30, 2025 | 10.28% |
| Mar 31, 2025 | 0.39% |
| Dec 31, 2024 | 75.96% |
| Sep 30, 2024 | -22.30% |
| Jun 30, 2024 | -2.34% |
| Mar 31, 2024 | -7.83% |
| Dec 31, 2023 | -74.60% |
| Sep 30, 2023 | -32.38% |
| Jun 30, 2023 | -101.52% |
| Mar 31, 2023 | -11.29% |
| Dec 31, 2022 | -18.88% |
| Sep 30, 2022 | -28.44% |
| Jun 30, 2022 | -16.84% |
| Mar 31, 2022 | -16.27% |
| Dec 31, 2021 | -12.47% |
| Sep 30, 2021 | 5.78% |
| Jun 30, 2021 | -32.34% |
| Mar 31, 2021 | -86.45% |
| Dec 31, 2020 | 37.48% |
| Sep 30, 2020 | 4.72% |
| Jun 30, 2020 | 33.01% |
| Mar 31, 2020 | -20.21% |
| Dec 31, 2019 | -8.59% |
| Sep 30, 2019 | -20.19% |
| Jun 30, 2019 | -20.24% |
| Mar 31, 2019 | -22.41% |
| Dec 31, 2018 | -16.66% |
| Sep 30, 2018 | -30.40% |
| Jun 30, 2018 | -21.03% |
| Mar 31, 2018 | 50.77% |
| Dec 31, 2017 | -80.17% |
| Sep 30, 2017 | -71.65% |
| Jun 30, 2017 | -75.06% |
| Mar 31, 2017 | -71.11% |
| Dec 31, 2016 | -95.98% |
| Sep 30, 2016 | -103.58% |
| Jun 30, 2016 | -87.37% |
| Mar 31, 2016 | -98.20% |